Brief: Arrowhead Pharmaceuticals Completes Enrollment In Global Phase 3 Yosemite Study Of Zodasiran For The Treatment Of Homozygous Familial Hypercholesterolemia
27/07/2026 12:34
BRIEF-Arrowhead Pharmaceuticals Completes Enrollment In Global Phase 3 Yosemite Study Of Zodasiran For The Treatment Of Homozygous Familial Hypercholesterolemia July 27 (Reuters) - Arrowhead Pharmaceuticals Inc ARWR.O:
ARROWHEAD PHARMACEUTICALS COMPLETES ENROLLMENT IN GLOBAL PHASE 3 YOSEMITE STUDY OF ZODASIRAN FOR THE TREATMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
ARROWHEAD PHARMACEUTICALS - YOSEMITE PHASE 3 STUDY COMPLETION ANTICIPATED IN MID-2027
Source text: ID:nBw2WZKmCa
Further company coverage: ARWR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arrowhead Pharmaceuticals
See all newsBrief: Uk's MHRA Authorises Redemplo For Adults With Familial Chylomicronaemia Syndrome
US STOCKS ON THE MOVE-Netflix, Coinbase Global, Accenture
US STOCKS ON THE MOVE-Bending Spoons, Skydance, Albertsons
US STOCKS ON THE MOVE-Albertsons, GlobalFoundries, American Electric Power, Fastenal
Brief: Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers